Proteomics reveals protein shifts in diabetic eye disease
Diabetic retinopathy, DR, is the leading cause of blindness and vision impairment in adults under 40 in developed countries. Many cases progress to vision-threatening stages, including proliferative diabetic retinopathy, PDR, and neovascular glaucoma, NVG. To investigate the molecular mechanisms driving this progression and identify potential biomarkers, Jae Won Oh and colleagues in South Korea used label-free quantification and tandem mass tagging to profile the clear fluid found at the front of the eye, known as aqueous humor, from patients with nonproliferative DR, NPDR, PDR and NVG. Their findings, published in Molecular & Cellular Proteomics, identified proteins that differed across DR stages.
The researchers used triple-quadrupole mass spectrometry to validate the potential biomarker expression, including APOB, TF and S100A7. These proteins showed markedly different expression levels between NPDR and PDR, as well as between PDR and NVG. Between NPDR and PDR, levels of S100A7, a protein linked to inflammation, increased, suggesting an early activation of inflammatory pathways. In contrast, structural lens proteins, more abundant in NPDR, began to decline in PDR, indicating a shift away from tissue maintenance toward stress response. As the disease advanced from PDR to NVG, proteins like APOB and TF, which are involved in fat transport and immune regulation, continued to rise in expression. APOB stood out as a key marker of the most severe stage, NVG, showing a clear increase in levels compared to earlier stages. These shifts in protein expression reflect how the disease moves from affecting eye tissue and vision early on to involving more serious inflammation and damage in the later stages.
These findings provide key insight into the molecular progression of diabetic retinopathy and highlight stage-specific protein changes that could serve as biomarkers. By uncovering potential targets for earlier diagnosis and tailored treatment, this study lays the groundwork for improved management of vision-threatening diabetic eye disease.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Bacteriophage protein could make queso fresco safer
Researchers characterized the structure and function of PlyP100, a bacteriophage protein that shows promise as a food-safe antimicrobial for preventing Listeria monocytogenes growth in fresh cheeses.
Building the blueprint to block HIV
Wesley Sundquist will present his work on the HIV capsid and revolutionary drug, Lenacapavir, at the ASBMB Annual Meeting, March 7–10, in Maryland.
Gut microbes hijack cancer pathway in high-fat diets
Researchers at the Feinstein Institutes for Medical Research found that a high-fat diet increases ammonia-producing bacteria in the gut microbiome of mice, which in turn disrupts TGF-β signaling and promotes colorectal cancer.
Mapping fentanyl’s cellular footprint
Using a new imaging method, researchers at State University of New York at Buffalo traced fentanyl’s effects inside brain immune cells, revealing how the drug alters lipid droplets, pointing to new paths for addiction diagnostics.
Designing life’s building blocks with AI
Tanja Kortemme, a professor at the University of California, San Francisco, will discuss her research using computational biology to engineer proteins at the 2026 ASBMB Annual Meeting.
Cholesterol as a novel biomarker for Fragile X syndrome
Researchers in Quebec identified lower levels of a brain cholesterol metabolite, 24-hydroxycholesterol, in patients with fragile X syndrome, a finding that could provide a simple blood-based biomarker for understanding and managing the condition.